Drug Trial Radar · NCT00216879
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis
Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
800
Actual
Start
Feb 2005
Primary completion
Not stated
Study completion Jul 2006
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial is to study the safety and efficacy of long term use of once daily applications, as needed, of calcipotriol plus betamethasone dipropionate gel, as compared to calcipotriol alone in the same gel. The primary response criteria will be the incidence of adverse drug reactions of any type, and the incidence of adverse events of concern associated with long-term corticosteroid use on the scalp.
Conditions
- Psoriasis of Scalp
Interventions
Calcipotriol plus betamethasone dipropionate gel (LEO 80185)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportions of patients who experience adverse drug reactions and the proportion of patients who experience adverse events of concern associated with long-term topical corticosteroid use on the scalp during the study
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
Clinique de Dermatologie
Moncton, Canada
Hørsholm Hospital, Dermatological Department
Hørsholm, Denmark
Hôpital Nord, Service de Dermatologie
Saint-Etienne, France
Universitätsklinikum Münster, Klinik und Poliklinik für Hautkrankheiten
Münster, Germany
Monklands Hospital, Department of Dermatology
Airdrie, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.